322 related articles for article (PubMed ID: 10828763)
1. Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy.
Hovind P; Tarnow L; Oestergaard PB; Parving HH
Kidney Int Suppl; 2000 Apr; 75():S56-61. PubMed ID: 10828763
[TBL] [Abstract][Full Text] [Related]
2. Plasma vascular endothelial growth factor in Japanese Type 2 diabetic patients with and without nephropathy.
Shimada K; Baba T; Neugebauer S; Onozaki A; Yamada D; Midorikawa S; Sato W; Watanabe T
J Diabetes Complications; 2002; 16(6):386-90. PubMed ID: 12477622
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of placental growth factor and soluble Fms-like tyrosine kinase 1 as predictors of all-cause and cardiovascular mortality in patients with Type 1 diabetes with and without diabetic nephropathy.
Theilade S; Lajer M; Jorsal A; Tarnow L; Parving HH; Rossing P
Diabet Med; 2012 Mar; 29(3):337-44. PubMed ID: 21988672
[TBL] [Abstract][Full Text] [Related]
4. Soluble CD40 ligand is elevated in type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function.
Lajer M; Tarnow I; Michelson AD; Jorsal A; Frelinger AL; Parving HH; Rossing P; Tarnow L
Platelets; 2010; 21(7):525-32. PubMed ID: 20701458
[TBL] [Abstract][Full Text] [Related]
5. Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy.
Tarnow L; Hildebrandt P; Hansen BV; Borch-Johnsen K; Parving HH
Diabetologia; 2005 Jan; 48(1):149-55. PubMed ID: 15616804
[TBL] [Abstract][Full Text] [Related]
6. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes.
Tarnow L; Hovind P; Teerlink T; Stehouwer CD; Parving HH
Diabetes Care; 2004 Mar; 27(3):765-9. PubMed ID: 14988299
[TBL] [Abstract][Full Text] [Related]
7. Circulating plasma vascular endothelial growth factor and microvascular complications of type 1 diabetes mellitus: the influence of ACE inhibition.
Chaturvedi N; Fuller JH; Pokras F; Rottiers R; Papazoglou N; Aiello LP;
Diabet Med; 2001 Apr; 18(4):288-94. PubMed ID: 11437859
[TBL] [Abstract][Full Text] [Related]
8. Progression of diabetic nephropathy: role of plasma homocysteine and plasminogen activator inhibitor-1.
Hovind P; Tarnow L; Rossing P; Teerlink T; Stehouwer CD; Emeis JJ; Parving HH
Am J Kidney Dis; 2001 Dec; 38(6):1376-80. PubMed ID: 11728978
[TBL] [Abstract][Full Text] [Related]
9. Plasma concentration of immunoreactive vascular endothelial growth factor and its relation to smoking.
Wasada T; Kawahara R; Katsumori K; Naruse M; Omori Y
Metabolism; 1998 Jan; 47(1):27-30. PubMed ID: 9440473
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor in diabetic nephropathy.
Lenz T; Haak T; Malek J; Gröne HJ; Geiger H; Gossmann J
Kidney Blood Press Res; 2003; 26(5-6):338-43. PubMed ID: 14610338
[TBL] [Abstract][Full Text] [Related]
11. Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively.
Hovind P; Rossing P; Tarnow L; Smidt UM; Parving HH
Kidney Int; 2001 Jul; 60(1):277-83. PubMed ID: 11422762
[TBL] [Abstract][Full Text] [Related]
12. Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment.
Lip PL; Belgore F; Blann AD; Hope-Ross MW; Gibson JM; Lip GY
Invest Ophthalmol Vis Sci; 2000 Jul; 41(8):2115-9. PubMed ID: 10892852
[TBL] [Abstract][Full Text] [Related]
13. Plasma and urinary vascular endothelial growth factor and diabetic nephropathy in Type 2 diabetes mellitus.
Kim NH; Kim KB; Kim DL; Kim SG; Choi KM; Baik SH; Choi DS; Kang YS; Han SY; Han KH; Ji YH; Cha DR
Diabet Med; 2004 Jun; 21(6):545-51. PubMed ID: 15154937
[TBL] [Abstract][Full Text] [Related]
14. Elevated placental growth factor (PlGF) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy.
Tarnow L; Astrup AS; Parving HH
Scand J Clin Lab Invest Suppl; 2005; 240():73-9. PubMed ID: 16112962
[TBL] [Abstract][Full Text] [Related]
15. Progression of diabetic nephropathy in normotensive type 1 diabetic patients.
Jacobsen P; Rossing K; Tarnow L; Rossing P; Mallet C; Poirier O; Cambien F; Parving HH
Kidney Int Suppl; 1999 Jul; 71():S101-5. PubMed ID: 10412749
[TBL] [Abstract][Full Text] [Related]
16. Increased vascular endothelial growth factor serum concentrations may help to identify patients with onset of type 1 diabetes during childhood at risk for developing persistent microalbuminuria.
Santilli F; Spagnoli A; Mohn A; Tumini S; Verrotti A; Cipollone F; Mezzetti A; Chiarelli F
J Clin Endocrinol Metab; 2001 Aug; 86(8):3871-6. PubMed ID: 11502826
[TBL] [Abstract][Full Text] [Related]
17. The early natural history of nephropathy in Type 1 Diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients.
Steinke JM; Sinaiko AR; Kramer MS; Suissa S; Chavers BM; Mauer M;
Diabetes; 2005 Jul; 54(7):2164-71. PubMed ID: 15983218
[TBL] [Abstract][Full Text] [Related]
18. Plasma growth differentiation factor-15 independently predicts all-cause and cardiovascular mortality as well as deterioration of kidney function in type 1 diabetic patients with nephropathy.
Lajer M; Jorsal A; Tarnow L; Parving HH; Rossing P
Diabetes Care; 2010 Jul; 33(7):1567-72. PubMed ID: 20357380
[TBL] [Abstract][Full Text] [Related]
19. Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy.
Lajer M; Tarnow L; Jorsal A; Teerlink T; Parving HH; Rossing P
Diabetes Care; 2008 Apr; 31(4):747-52. PubMed ID: 18162497
[TBL] [Abstract][Full Text] [Related]
20. PC-1 amino acid variant (K121Q) has no impact on progression of diabetic nephropathy in type 1 diabetic patients.
Jacobsen P; Grarup N; Tarnow L; Parving HH; Pedersen O
Nephrol Dial Transplant; 2002 Aug; 17(8):1408-12. PubMed ID: 12147787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
